Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Gains from Investment Securities: 2023-2025

Historic Gains from Investment Securities for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to $5.6 million.

  • Contineum Therapeutics' Gains from Investment Securities rose 35.79% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 35.79%. This contributed to the annual value of $4.0 million for FY2024, which is 51.27% up from last year.
  • Contineum Therapeutics' Gains from Investment Securities amounted to $5.6 million in Q3 2025, which was up 0.30% from $5.6 million recorded in Q2 2025.
  • Contineum Therapeutics' 5-year Gains from Investment Securities high stood at $6.6 million for Q4 2024, and its period low was -$11,000 during Q2 2024.
  • Over the past 3 years, Contineum Therapeutics' median Gains from Investment Securities value was $1.7 million (recorded in 2023), while the average stood at $2.6 million.
  • Per our database at Business Quant, Contineum Therapeutics' Gains from Investment Securities soared by 57,737.26% in 2024 and then plummeted by 93.06% in 2025.
  • Quarterly analysis of 3 years shows Contineum Therapeutics' Gains from Investment Securities stood at $574,000 in 2023, then spiked by 1,042.33% to $6.6 million in 2024, then skyrocketed by 35.79% to $5.6 million in 2025.
  • Its Gains from Investment Securities stands at $5.6 million for Q3 2025, versus $5.6 million for Q2 2025 and $200,000 for Q1 2025.